Hexarelin sourcing should not be treated as a simple short-peptide quote request. Although Hexarelin is a six-amino-acid peptide, B2B buyers still need to clarify sequence notation, D-amino acid references, C-terminal amidation, salt form, documentation scope, quote unit, MOQ, lead time, and supplier capability before comparing offers.
A common sourcing mistake is assuming that a short peptide automatically requires less documentation. For Hexarelin, the sequence notation and structural specification matter. A supplier may provide a competitive price, but if the documentation does not clearly confirm the expected sequence, salt form, batch number, and analytical support, the quote is not ready for serious comparison.
This guide is written for distributors, private label brand owners, OEM project teams, formulation consultants, and procurement buyers evaluating Hexarelin in bulk powder, lyophilized vial, or custom fill project formats.
It is a B2B sourcing and specification reference. It does not provide end-user application guidance, clinical recommendations, or outcome claims.
What Hexarelin Is from a Sourcing Perspective
From a sourcing perspective, Hexarelin should be reviewed first as a defined peptide material with specific identity, structural notation, and documentation requirements.
Common identification fields include:
- Peptide name: Hexarelin.
- CAS number: 140703-51-1.
- Molecular formula: C47H58N12O6.
- Molecular weight: approximately 887.1 g/mol for the free base reference, depending on form and supplier documentation.
- Sequence reference: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2.
- Structural features to confirm: D-amino acid residues and C-terminal amidation.
- Appearance: commonly supplied as white to off-white lyophilized powder.
- Common B2B formats: bulk powder and lyophilized vial.
The sourcing point is not just whether a supplier lists “Hexarelin.” Buyers should confirm whether the supplier’s specification sheet, COA, HPLC report, LC-MS report where available, label, and packing information all align with the same material definition.
D-amino acid notation and C-terminal amidation are not decorative details. They are specification fields that can affect supplier qualification, documentation review, and quote comparison.
Why Hexarelin Sourcing Projects Stall and How to Avoid It
Hexarelin sourcing projects often stall when buyers treat the SKU as a simple catalog peptide and request price before defining the material and project scope.
Common buyer mistakes at the start of a project
Common early mistakes include:
- Requesting “Hexarelin” without confirming sequence notation.
- Not asking whether D-amino acid residues are stated in the specification.
- Assuming C-terminal amidation is automatically covered.
- Comparing quotes before receiving a specification sheet.
- Accepting a USD/vial quote without fill amount.
- Treating a catalog listing as proof of current stock.
- Accepting documentation only after payment.
- Comparing prices without knowing whether LC-MS or other identity confirmation is available.
- Asking for a custom fill quote without defining fill amount, vial format, and documentation scope.
These mistakes usually create delays after the first quotation, when the buyer realizes that price alone does not define the project.
What to clarify before comparing quotes
Before comparing Hexarelin suppliers, buyers should clarify:
- Required format: bulk powder, lyophilized vial, or custom fill.
- Sequence reference and D-amino acid notation.
- C-terminal amidation confirmation.
- Salt form or counterion where relevant.
- Target quantity or fill amount.
- Quote basis: USD/g, USD/mg, USD/vial, or USD/box.
- Purity threshold and analytical method.
- Documentation package.
- MOQ basis.
- Lead time scope.
- Packaging and labeling requirements.
- Destination-market shipment requirements.
If suppliers cannot answer these points in the same structure, their prices are not yet comparable.
For unit comparison logic, see WUMO's guide: Peptide Quote Units Explained: USD/g vs USD/vial vs USD/box.
Hexarelin Specification Fields Every B2B Buyer Should Review
A specification sheet should define what is being quoted. Without a specification sheet, buyers may be comparing different forms, documentation packages, or quality expectations under the same product name.
Identity and structural parameters
Buyers should confirm:
- Product name and naming consistency.
- CAS number.
- Sequence reference.
- D-amino acid notation.
- C-terminal amidation.
- Molecular formula.
- Molecular weight.
- Salt form or counterion where relevant.
- Batch number once a batch is allocated.
The sequence should not be shortened into a vague “modified peptide” description. If D-residue notation or C-terminal amidation is missing from the specification sheet, the buyer should request clarification before comparing the quote with another supplier.
Quality parameters
Key quality fields may include:
- Purity threshold.
- Analytical method.
- HPLC chromatogram availability.
- Water content where applicable.
- Residual solvent limits where applicable.
- Appearance.
- Storage condition.
- Shelf-life or retest statement where available.
Purity should be reviewed with method and documentation. A visible “98%” or “99%” figure is not enough unless the buyer understands whether it is supported by HPLC and whether the report is batch-specific.
Salt form and counterion basis
Hexarelin may be quoted under different material forms depending on supplier practice. Buyers should ask:
- What form is being quoted?
- Is the form stated on the specification sheet?
- Is it reflected on the COA?
- Is the quoted weight based on gross material weight or peptide-content basis?
- Are two suppliers quoting the same material form?
If one supplier’s quote is based on one form and another supplier’s quote is based on a different form, direct USD/g comparison can be misleading.
Physical characteristics
Typical specification review may include:
- White to off-white lyophilized powder.
- Storage condition.
- Moisture data where available.
- Residual solvent limits where applicable.
- Packaging format.
- Shelf-life or retest statement where available.
Physical characteristics should be treated as sourcing and specification fields, not as end-use guidance.
Documentation: What to Request, When, and Why
Documentation should be requested before a buyer commits to a first order. It is part of supplier qualification, not merely a shipment attachment.
Certificate of Analysis
A COA should be batch-specific. A COA without batch number has limited traceability value.
A useful COA may include:
- Product name.
- Batch number.
- Purity result.
- Test method.
- Appearance.
- Molecular weight or identity reference where applicable.
- Water content where applicable.
- Storage condition.
- Analysis date.
- Issuing entity.
The COA should match the batch being quoted or shipped. If the supplier only provides a generic COA, the buyer should request clarification before treating the quote as ready for comparison.
HPLC purity report
An HPLC report helps support the purity figure shown on the COA.
Buyers should check:
- Does the report include a chromatogram?
- Does the batch number match the COA?
- Are method parameters stated?
- Is the purity figure consistent with the specification sheet?
- Is the report batch-specific or representative?
- Is the purity basis clear?
A purity number without chromatogram or method support is harder to evaluate.
LC-MS or mass confirmation
LC-MS or mass confirmation helps support molecular identity review. For Hexarelin, it is useful because the buyer should confirm not only the product name, but also whether the reported mass aligns with the expected sequence and structural specification.
A useful mass confirmation document may include:
- Observed mass.
- Theoretical mass.
- Spectrum or method reference.
- Batch or sample reference.
- Test date.
LC-MS may not fully answer every structural question, but it is still an important supplier qualification document. If additional identity confirmation is required by the buyer's downstream review process, it should be requested explicitly at RFQ stage.
SDS and specification sheet
The SDS supports safety, handling, storage, and transport review. It does not confirm peptide identity or purity.
The specification sheet defines the product standard. It should be reviewed before formal quotation whenever possible.
For Hexarelin, a specification sheet may include:
- Product name.
- CAS number.
- Sequence reference.
- D-amino acid notation.
- C-terminal amidation.
- Molecular formula.
- Molecular weight.
- Appearance.
- Purity specification.
- Analytical method.
- Water content where applicable.
- Storage condition.
- Packaging format.
- Shelf-life or retest statement where available.
For broader documentation review, see WUMO's research-grade peptide shipment documents checklist.
Red Flags Buyers Should Watch For
Red flags do not always mean a supplier is unusable. They mean the buyer should slow down and clarify before moving forward.
Documentation red flags
Watch for:
- Sequence listed without D-amino acid notation.
- C-terminal amidation not referenced.
- COA without batch number.
- Purity number without HPLC chromatogram.
- LC-MS unavailable or unexplained for first-time qualification.
- SDS not available for shipment discussion.
- Specification sheet missing at RFQ stage.
- Generic COA reused for multiple batches.
- Documents provided only after payment with no representative examples.
A low price with weak documentation is not a strong quote. It is an incomplete quote.
Quote and pricing red flags
Common pricing red flags include:
- Quote issued without material form.
- USD/vial quote without fill amount.
- USD/box quote without vials per box.
- MOQ given as a single number with no basis.
- Lead time stated without scope.
- Documentation scope not listed.
- Price significantly lower than alternatives but testing scope is unclear.
The buyer should be able to tell what is included and what is excluded. If the quote requires guesswork, it is not ready for final comparison.
Supplier response red flags
Supplier communication can reveal process maturity.
Watch for:
- Generic catalog reply that does not address sequence or format.
- No answer on stock vs. made-to-order.
- No explanation of MOQ basis.
- Lead time stated as one number without scope.
- No clear path for documentation review.
- Custom fill discussed without asking for fill amount or project scope.
- No technical or QC support available when needed.
A stronger supplier response usually includes clarifying questions before a formal quotation is issued.
Bulk Powder vs. Lyophilized Vial: Choosing the Right Format
Format choice should follow project stage, quantity, documentation needs, and downstream capability.
When bulk powder is the right starting point
Bulk powder may make sense when:
- The buyer has downstream processing or filling capability.
- The buyer wants to separate material cost from vialing and packaging cost.
- The project requires custom fill discussion later.
- The sourcing comparison is made at gram or milligram level.
- The buyer is building internal catalog inventory or formulation inputs.
Bulk powder quotes are usually stated in USD/g or USD/mg. Buyers should confirm whether the quote is based on gross material weight or another basis.
When lyophilized vial format makes more sense
Lyophilized vial format may be more suitable when the buyer needs a defined vial-based project format.
Important variables include:
- Fill amount per vial.
- Vial size.
- Vial component.
- Label scope.
- Box configuration.
- Documentation package.
- MOQ.
- Lead time.
- Quote unit.
A vial quote is not meaningful without fill amount. A box quote is not meaningful without vial count and contents.
For broader vial project scoping, see WUMO's lyophilized peptide vial sourcing guide.
When to discuss custom fill
Custom fill may be relevant when catalog fill amounts do not match the buyer's specification.
Buyers should be ready to provide:
- Target fill amount.
- Target quantity.
- Vial format.
- Packaging scope.
- Documentation requirements.
- Labeling or private label requirements.
- Project timeline.
- NDA requirement where applicable.
Custom fill is usually not the fastest path for early pilot-stage evaluation. It is better suited when the buyer has a clearer project specification.
MOQ and Lead Time: What the Numbers Actually Mean
MOQ and lead time should be interpreted by project type, not as isolated numbers.
MOQ: reading between the lines
An MOQ may be based on:
- Existing stock.
- New synthesis batch.
- Minimum order value.
- Vial filling setup.
- Packaging procurement.
- Custom label or box requirements.
- Documentation workload.
For Hexarelin, buyers should ask whether the MOQ applies to existing material, a new batch, catalog vials, or a custom fill run.
A “100 vials” MOQ means little without knowing fill amount per vial and total material requirement.
If the buyer is at pilot stage, it may be better to ask about sample quantity, phased ordering, or representative documentation rather than pushing immediately for a custom project.
Lead time: ask for the full picture
A lead time such as “2–4 weeks” is not enough unless the scope is defined.
Buyers should ask whether it includes:
- Material availability or synthesis.
- QC testing.
- Documentation preparation.
- Vial filling or lyophilization where applicable.
- Packaging.
- Export preparation.
- Dispatch.
- Shipping.
For projects requiring additional identity confirmation or custom vial formats, QC and documentation timing can matter as much as production timing. The buyer should request a stage-by-stage lead time where possible.
For broader MOQ and lead time review, see WUMO's bulk peptide purchasing guide.
How to Prepare a Stronger RFQ for Hexarelin
A stronger RFQ reduces back-and-forth and helps suppliers provide comparable quotes.
What a better RFQ includes
A practical Hexarelin RFQ should include:
- Required format: bulk powder, lyophilized vial, or custom fill.
- Sequence reference or required structural notation.
- C-terminal amidation confirmation.
- Target quantity with unit.
- Preferred quote basis: USD/g, USD/mg, USD/vial, or USD/box.
- Purity requirement and purity basis if relevant.
- Required documents: COA, HPLC, LC-MS, SDS, specification sheet.
- Fill amount per vial if applicable.
- Packaging or labeling scope.
- Target delivery timeline.
- Destination country or region for shipment planning.
- NDA requirement if project details are sensitive.
What does not need to be included
A B2B sourcing RFQ does not need to include end-use details, user instructions, or application claims. The supplier needs specification, quantity, format, documentation requirements, and shipment context to quote the project properly.
If additional regulatory review is required for the buyer's market, that should be handled by the buyer's own compliance or regulatory team.
Supplier Qualification Checkpoints for Hexarelin Projects
Supplier qualification should evaluate both product documentation and project capability.
Useful questions include:
- Can you provide a specification sheet before formal quotation?
- Does the specification sheet include D-amino acid notation?
- Is C-terminal amidation confirmed?
- Is batch-specific COA available?
- Is HPLC chromatogram available with the COA?
- Is LC-MS or mass confirmation available?
- What is the MOQ basis?
- Is the material in stock or made to order?
- What does the quoted lead time include?
- Can you support lyophilized vial format?
- Can you support custom fill or private label discussion?
- What documents are available before payment or deposit?
A stronger supplier response usually:
- Defines material form clearly.
- States quote unit and quantity basis.
- Explains MOQ and lead time assumptions.
- Provides representative documentation scope.
- States what is included and excluded.
- Asks clarifying questions before final quotation.
- Avoids overpromising on unconfirmed stock or documentation.
For a broader supplier review framework, see WUMO's peptide supplier qualification checklist.
What WUMO Reviews Before Issuing a Formal Quotation
WUMO prefers to clarify project scope before issuing a formal quotation. This helps avoid quoting the wrong format, unit, documentation scope, or MOQ basis.
For Hexarelin project discussions, WUMO may review:
- Required format: bulk powder, vial, or custom fill.
- Sequence and structural specification alignment.
- Target quantity.
- Quote unit preference.
- Fill amount if vial format is requested.
- Documentation scope.
- Batch traceability requirements.
- Packaging and label scope.
- MOQ and lead time expectations.
- Destination-market shipment considerations.
- Whether NDA is needed before detailed discussion.
A fast quote is not always a better quote. For specification-sensitive peptide projects, a quote is more useful when the product definition is clear.
How WUMO Supports Qualified Hexarelin B2B Sourcing Projects
WUMO supports qualified B2B buyers with Hexarelin sourcing discussion, specification review, documentation review, and project quotation support.
For Hexarelin projects, WUMO can help buyers clarify:
- Bulk powder or lyophilized vial format.
- Documentation scope.
- COA, HPLC, LC-MS, SDS, and specification sheet availability.
- Sequence and structural specification alignment.
- MOQ and volume tier discussion.
- Lead time assumptions.
- Quote basis.
- Custom fill feasibility.
- Neutral label or private label discussion.
- Packaging scope.
- Project fit before formal quotation.
Availability may vary by batch, project type, destination requirement, and buyer specification. Buyers are encouraged to state format, documentation, MOQ, and packaging requirements before quotation so the project can be reviewed properly.
Frequently Asked Questions
What is Hexarelin and what is its CAS number?
Hexarelin is a synthetic peptide commonly referenced in sourcing documentation by CAS number 140703-51-1. Buyers should verify CAS number, sequence reference, molecular weight, and batch documentation against the supplier's specification sheet and COA.
What does the D-amino acid content of Hexarelin mean for sourcing and documentation?
It means buyers should review identity and sequence documentation carefully. Specification sheet, LC-MS or mass confirmation where available, and batch-linked analytical records can help support supplier qualification.
Why does C-terminal amidation matter when sourcing Hexarelin?
C-terminal amidation is a structural feature that should be confirmed in the specification. If it is not stated, the buyer should request clarification before comparing the quote with another supplier.
What is the difference between Hexarelin free base and Hexarelin acetate salt in a sourcing context?
The difference is relevant to material form, molecular weight reference, and quote comparison. Buyers should confirm the exact form being quoted and ensure the same form is used across specification sheet, COA, and quotation.
What purity threshold and basis should I specify for a Hexarelin B2B project?
Purity threshold depends on project requirements and supplier capability. Buyers should define the required threshold in the specification sheet and confirm that COA and HPLC results support the same standard.
Why is LC-MS confirmation important for a short peptide like Hexarelin?
A short peptide still requires identity review. LC-MS or mass confirmation can help support molecular identity and confirm that the observed mass aligns with the expected sequence and structural reference.
What fill amounts are typically available for lyophilized Hexarelin vials?
Fill amounts are not standardized across suppliers. Buyers should specify the required fill amount in the RFQ and confirm whether the supplier offers catalog fill, custom fill, or private label vial options.
How do I compare Hexarelin quotes from suppliers using different unit bases?
Normalize quotes to the same peptide-content basis, such as USD/mg or USD/g. Then compare documentation, MOQ, lead time, packaging, vial fill amount, and shipment scope separately.
What is a realistic MOQ for Hexarelin in lyophilized vial format?
MOQ varies by supplier, fill amount, vial format, packaging scope, and whether the project is catalog fill or custom fill. Buyers should request volume tiers and a clear MOQ basis before comparing suppliers.
What are the most common red flags when evaluating a Hexarelin supplier?
Red flags include missing sequence notation, unclear salt form, missing batch number, purity claim without HPLC support, no LC-MS option, undefined MOQ basis, lead time without scope, and documentation only available after payment.
What should a Hexarelin RFQ include that a standard peptide RFQ might not?
A Hexarelin RFQ should clearly state sequence reference, D-amino acid notation, C-terminal amidation, form preference, documentation scope, and identity confirmation expectations in addition to quantity, format, and quote unit.
Who is responsible for confirming Hexarelin import compliance in the destination market?
The buyer is responsible for confirming import, registration, labeling, distribution, and downstream compliance obligations in the destination market. Supplier documentation supports sourcing review but does not guarantee regulatory approval or import clearance.
CTA
B2B buyers evaluating Hexarelin as a sourcing project are welcome to request WUMO's documentation scope and project capability overview.
Specification review, sequence confirmation, and quotation discussion are available for qualified B2B inquiries.